sarpogrelate has been researched along with Ischemia in 6 studies
sarpogrelate: structure given in first source
Ischemia: A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to determine the effect of a combination of bone marrow mononuclear cell (BM-MNC) implantation and sarpogrelate, a selective 5-HT(2A) antagonist, on endothelial function in patients with critical limb ischemia (CLI)." | 9.14 | Sarpogrelate hydrochloride, a selective 5-hydroxytryptamine(2A) antagonist, augments autologous bone marrow mononuclear cell implantation-induced improvement in endothelium-dependent vasodilation in patients with critical limb ischemia. ( Chayama, K; Goto, C; Higashi, Y; Miyazaki, M; Sanada, H; Sueda, T, 2010) |
| " However, it remains unknown as to whether the administration of sarpogrelate, a 5-hydroxytryptamine type 2 antagonist, improves the prognosis after endovascular therapy for critical limb ischemia (CLI)." | 7.80 | Effect of sarpogrelate treatment on the prognosis after endovascular therapy for critical limb ischemia. ( Iida, O; Kaneto, H; Katakami, N; Matsuoka, TA; Shimomura, I; Takahara, M, 2014) |
| " This study was designed to examine the impact of combined multipotent adipose-derived stromal cells (mADSCs) and sarpogrelate treatment on aging hindlimb ischemia and the mechanism of action involved." | 7.79 | Adipose stromal cell and sarpogrelate orchestrate the recovery of inflammation-induced angiogenesis in aged hindlimb ischemic mice. ( Bu, Q; Cao, F; Cheng, K; Da, H; Fan, W; Han, Y; Li, C; Li, X; Qin, X; Ren, J; Tong, C; Wang, S; Zhou, R, 2013) |
| "The effectiveness of sustained-release basic fibroblast growth factor (bFGF) in potentiating arteriogenesis and angiogenesis was evaluated, as well as determining whether chronic oral administration of sarpogrelate, a serotonin blocker, would further increase collateral blood flow in the rabbit hindlimb following surgical induction of ischemia by femoral artery extraction." | 7.73 | Combined treatment of sustained-release basic fibroblast growth factor and sarpogrelate enhances collateral blood flow effectively in rabbit hindlimb ischemia. ( Arai, Y; Chandra, S; Fujita, M; Hirose, K; Huang, Y; Komeda, M; Marui, A; Sakaguchi, H; Tabata, Y, 2006) |
| "The purpose of this study was to determine the effect of a combination of bone marrow mononuclear cell (BM-MNC) implantation and sarpogrelate, a selective 5-HT(2A) antagonist, on endothelial function in patients with critical limb ischemia (CLI)." | 5.14 | Sarpogrelate hydrochloride, a selective 5-hydroxytryptamine(2A) antagonist, augments autologous bone marrow mononuclear cell implantation-induced improvement in endothelium-dependent vasodilation in patients with critical limb ischemia. ( Chayama, K; Goto, C; Higashi, Y; Miyazaki, M; Sanada, H; Sueda, T, 2010) |
| " However, it remains unknown as to whether the administration of sarpogrelate, a 5-hydroxytryptamine type 2 antagonist, improves the prognosis after endovascular therapy for critical limb ischemia (CLI)." | 3.80 | Effect of sarpogrelate treatment on the prognosis after endovascular therapy for critical limb ischemia. ( Iida, O; Kaneto, H; Katakami, N; Matsuoka, TA; Shimomura, I; Takahara, M, 2014) |
| " This study was designed to examine the impact of combined multipotent adipose-derived stromal cells (mADSCs) and sarpogrelate treatment on aging hindlimb ischemia and the mechanism of action involved." | 3.79 | Adipose stromal cell and sarpogrelate orchestrate the recovery of inflammation-induced angiogenesis in aged hindlimb ischemic mice. ( Bu, Q; Cao, F; Cheng, K; Da, H; Fan, W; Han, Y; Li, C; Li, X; Qin, X; Ren, J; Tong, C; Wang, S; Zhou, R, 2013) |
| "The combined treatment of sustained-release basic fibroblast growth factor (Sr-bFGF) and a 5-hydroxytryptamine(2A) blocker, sarpogrelate, was evaluated to see whether it reversed the impaired collateral circulation in diabetic (DM) mouse hindlimb ischemia." | 3.74 | New therapeutic approach for impaired arteriogenesis in diabetic mouse hindlimb ischemia. ( Arai, Y; Bir, SC; Esaki, J; Fujita, M; Hirose, K; Huang, Y; Ikeda, T; Komeda, M; Marui, A; Sakaguchi, H; Tabata, Y, 2008) |
| "The effectiveness of sustained-release basic fibroblast growth factor (bFGF) in potentiating arteriogenesis and angiogenesis was evaluated, as well as determining whether chronic oral administration of sarpogrelate, a serotonin blocker, would further increase collateral blood flow in the rabbit hindlimb following surgical induction of ischemia by femoral artery extraction." | 3.73 | Combined treatment of sustained-release basic fibroblast growth factor and sarpogrelate enhances collateral blood flow effectively in rabbit hindlimb ischemia. ( Arai, Y; Chandra, S; Fujita, M; Hirose, K; Huang, Y; Komeda, M; Marui, A; Sakaguchi, H; Tabata, Y, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takahara, M | 1 |
| Kaneto, H | 1 |
| Katakami, N | 1 |
| Iida, O | 1 |
| Matsuoka, TA | 1 |
| Shimomura, I | 1 |
| Higashi, Y | 1 |
| Miyazaki, M | 1 |
| Goto, C | 1 |
| Sanada, H | 1 |
| Sueda, T | 1 |
| Chayama, K | 1 |
| Iwabayashi, M | 1 |
| Taniyama, Y | 1 |
| Sanada, F | 1 |
| Azuma, J | 1 |
| Iekushi, K | 1 |
| Kusunoki, H | 1 |
| Chatterjee, A | 1 |
| Okayama, K | 1 |
| Rakugi, H | 1 |
| Morishita, R | 1 |
| Fan, W | 1 |
| Li, C | 2 |
| Qin, X | 1 |
| Wang, S | 1 |
| Da, H | 1 |
| Cheng, K | 1 |
| Zhou, R | 1 |
| Tong, C | 1 |
| Li, X | 1 |
| Bu, Q | 1 |
| Han, Y | 1 |
| Ren, J | 1 |
| Cao, F | 1 |
| Hirose, K | 2 |
| Fujita, M | 2 |
| Marui, A | 2 |
| Arai, Y | 2 |
| Sakaguchi, H | 2 |
| Huang, Y | 2 |
| Chandra, S | 1 |
| Tabata, Y | 2 |
| Komeda, M | 2 |
| Bir, SC | 1 |
| Esaki, J | 1 |
| Ikeda, T | 1 |
1 trial available for sarpogrelate and Ischemia
| Article | Year |
|---|---|
Sarpogrelate hydrochloride, a selective 5-hydroxytryptamine(2A) antagonist, augments autologous bone marrow mononuclear cell implantation-induced improvement in endothelium-dependent vasodilation in patients with critical limb ischemia.
Topics: Acetylcholine; Aged; Bone Marrow Transplantation; Combined Modality Therapy; Endothelium, Vascular; | 2010 |
5 other studies available for sarpogrelate and Ischemia
| Article | Year |
|---|---|
Effect of sarpogrelate treatment on the prognosis after endovascular therapy for critical limb ischemia.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Critical Illness; Disease-Free Survival; Endovascular | 2014 |
Role of serotonin in angiogenesis: induction of angiogenesis by sarpogrelate via endothelial 5-HT1B/Akt/eNOS pathway in diabetic mice.
Topics: Angiogenesis Inducing Agents; Animals; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic An | 2012 |
Adipose stromal cell and sarpogrelate orchestrate the recovery of inflammation-induced angiogenesis in aged hindlimb ischemic mice.
Topics: Adipose Tissue; Aging; Angiogenesis Inducing Agents; Animals; Disease Models, Animal; Hindlimb; Infl | 2013 |
Combined treatment of sustained-release basic fibroblast growth factor and sarpogrelate enhances collateral blood flow effectively in rabbit hindlimb ischemia.
Topics: Animals; Collateral Circulation; Disease Models, Animal; Drug Combinations; Fibrinolytic Agents; Fib | 2006 |
New therapeutic approach for impaired arteriogenesis in diabetic mouse hindlimb ischemia.
Topics: Animals; Base Sequence; Collateral Circulation; Delayed-Action Preparations; Diabetes Mellitus, Expe | 2008 |